Depression Therapeutics Market To Surpass US$ 14,814.9 Million Threshold By 2027 - Pfizer, Inc., Eli, Lilly and Company, AstraZeneca, Plc, Allergan Plc

The high prevalence and incidence rate of mental disorders such as anxiety, major depressive disorder, and associated co-morbidities are playing a significant role in the overall development of the depression therapeutics market. According to the World Health Organization, depression is a common mental disorder and one of the main causes of disability worldwide. Globally, an estimated 264 million people are affected by depression. More women are affected than men. Low costs of antidepressant therapies coupled with a lack of alternative therapies are also augmenting the growth of the market. Growing awareness regarding depression and various treatments among people are again supporting the growth of the depression therapeutics market.

Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1307

In March 2019, Sage Therapeutics announced the launch of postpartum depression (PPD) therapy Zulresso (brexanolone) to treat Central nervous system (CNS) disorder

In January 2019, Otsuka America, Inc., and Click Therapeutics, Inc., announced that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD), with the intent to address unmet medical needs among this patient population and to improve outcomes

In February 2021, Intra-Cellular Therapies, Inc. announced that it has submitted supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for two indications for CAPLYTA (lumateperone): 1) as monotherapy; and 2) as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults

In April 2021, The Milken Institute’s Center for Strategic Philanthropy and the Baszucki Brain Research Fund announced the launch of a dedicated grant program aimed at advancing therapeutic discovery for bipolar disorder (BD)

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1307

Therapeutic interventions in the field of clinical depression are divided into distinct subspecialties. The two major categories are cognitive behavioral therapy, which aims to improve and change the thought patterns and the emotions of the patient; and psychodynamic therapy, which aims to find out the causes of the depression, the triggers that initiate the depressive episodes, the events or circumstances that led to the development of the disorder, and the means to prevent or reduce future recurrences. Depression Therapeutic Psychotherapy attempts to determine and treat the cognitive-behavioral factors that are associated with the cause of the depression

North America is expected to lead the global depression therapeutics market and this is accredited to the growing FDA approval for the launch of novel therapies for treating depression disorder. For instance, in March 2019, The U.S. Food and Drug Administration approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults

Purchase this Report Here – https://www.coherentmarketinsights.com/insight/buy-now/1307

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.